Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$185.68 USD

185.68
1,137,205

+0.90 (0.49%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $185.63 -0.05 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Acorda (ACOR) Q4 Earnings Miss Estimates, Revenues Beat

Acorda (ACOR) misses on earnings in Q4 but beats on revenue estimates. The company's key drug Ampyra witnesses an increase in sales both year over year and sequentially.

    FDA Sets the Stage for Earlier-Stage Alzheimer's Treatments

    FDA's proposed guidelines come in a week when major disappointments in the field were announced by companies developing drugs to treat Alzheimer's.

      Alkermes (ALKS) Beats Q4 Earnings, Revenue Estimates

      Alkermes (ALKS) tops earnings and sales estimates in the fourth quarter of 2017 on the back of strong growth of Vivitrol and Aristada. The company provided a decent outlook for 2018.

        Merck (MRK) Halts Another Late Stage Study on Alzheimer's

        Merck (MRK) stalls a phase III study evaluating verubecestat for the treatment of prodromal Alzheimer's disease on the recommendation of an external data monitoring committee.

          The Zacks Analyst Blog Highlights: Novartis, BP and Biogen

          The Zacks Analyst Blog Highlights: Novartis, BP and Biogen

            Biogen Halts Tysabri Development in Stroke as Study Fails

            Biogen's Tysabri (natalizumab) falters in a phase IIb study, evaluating it for acute ischemic stroke (AIS) indication.

              Biogen (BIIB) Q4 Earnings Miss, Sales Top, 2018 View Upbeat

              Biogen (BIIB) beats estimates for earnings but misses the same for sales in Q4. The outlook issued for 2018 looks fairly upbeat.

                Biogen (BIIB) Q4 Earnings Miss, Sales Top, Stock Up

                Biogen (BIIB) beats estimates for earnings but misses the same for sales in Q4. The outlook issued for 2018 looks fairly upbeat.

                  What's in the Cards for Biogen (BIIB) This Earnings Season?

                  On the Q4 call, investor focus will be on the impact of Roche's newly launched drug, Ocrevus on Biogen's (BIIB) MS franchise, and Spinraza's performance.

                    Sanofi to Acquire Haemophilia Focused Bioverativ, Stock Dips

                    Sanofi (SNY) is set to acquire blood disorder focused biopharmaceutical company, Bioverativ, for $11.6 billion.

                      Arpita Dutt headshot

                      3 Pharma and Biotech Stocks to Watch Out for in 2018

                      Here is a look at three pharma and biotech stocks including Alkermes (ALKS) that look well-positioned for 2018.

                        Roche MS Drug Ocrevus Gets Marketing Authorization in Europe

                        Roche's (RHHBY) multiple sclerosis drug Ocrevus gets approval in Europe thereby boosting its neuroscience portfolio. The drug is already approved in the United States.

                          Pfizer to Stall R&D for Alzheimer's/Parkinson's, Cut Jobs

                          Pfizer (PFE) will reportedly end R&D efforts in Alzheimer's and Parkinson's disease areas, which will result in about 300 job cuts.

                            Arpita Dutt headshot

                            Biotech Stock Roundup: GWPH Submits Epidiolex in the EU, Sangamo Inks Deal with Pfizer

                            Collaboration agreements announced by companies like Sangamo (SGMO) and the submission of a regulatory application for GW's Epidiolex were the key highlights this week in the biotech sector.

                              Biogen's Alzheimer's Drug Misses Goal in Interim Analysis

                              Biogen (BIIB) Alzheimer's candidate, BAN2401, failed to meet the criteria for success based on a 12 months interim analysis as the primary endpoint in a mid-stage trial.

                                The Zacks Analyst Blog Highlights: Pfizer, FedEx, Abbott, Biogen and Marathon Petroleum

                                The Zacks Analyst Blog Highlights: Pfizer, FedEx, Abbott, Biogen and Marathon Petroleum

                                  Biogen, Ionis Ink Deal for Spinal Muscular Atrophy Therapies

                                  Biogen (BIIB) expands collaboration with Ionis to identify new drug candidates for the treatment of SMA.

                                    Arpita Dutt headshot

                                    Biotech Stock Roundup: Label Expansion for Exelixis's Cabometyx, FDA Nod for Spark's Gene Therapy

                                    A one-time gene therapy for an inherited retinal disease gained FDA approval this week while Exelixis's (EXEL) Cabometyx can now be used in treatment-naive advanced renal cell carcinoma patients.

                                      Arpita Dutt headshot

                                      Biotech Stock Roundup: FDA Nod for Amgen PCSK9 Inhibitor, Revance Up on RT002 Data

                                      Data presentations and regulatory updates were the key highlights this week with companies like AbbVie (ABBV) and Clovis providing data on their pipeline candidates.

                                        Biogen Acquires Worldwide License for Alkermes' MS Candidate (revised)

                                        The deal will be beneficial for both companies as it will reduce costs and bring in a strong partner for Alkermes.

                                          Arpita Dutt headshot

                                          Biotech Stock Roundup: Regeneron Down on Eylea Data, Biogen-Alkermes in MS Deal

                                          While there were not too many updates this week, companies like Regeneron (REGN) and Biogen were in the news related to their pipeline.

                                            Mark Vickery headshot

                                            Top Research Reports for Amazon, AbbVie & Biogen

                                            Today's Research Daily features new research reports on 16 major stocks, including Amazon (AMZN), AbbVie (ABBV) and Biogen (BIIB).

                                              Biogen Acquires Worldwide License for Alkermes' MS Candidate

                                              Biogen (BIIB) and Alkermes clinch collaboration agreement to develop and commercialize Alkermes' multiple sclerosis candidate, ALKS8700.

                                                Zacks Value Trader Highlights: General Electric, Macy's, Biogen, Chipotle and Exxon Mobil

                                                Zacks Value Trader Highlights: General Electric, Macy's, Biogen, Chipotle and Exxon Mobil

                                                  Tracey Ryniec headshot

                                                  Should You Buy the Beaten Down Blue-Chip Stocks?

                                                  Just because a stock plunges to multi-year lows, that doesn't mean it's a value stock.